.
MergerLinks Header Logo

Announced

AGC to acquire Molmed for $267m.

Financials

Edit Data
Transaction Value£217m
Consideration TypeCash
Capital Owned-
Capital Bid For100%
EV/Sales6.6x
EV/EBITDA-
Share Price Premium110.3%
One Off Charge-

Tags

Edit

Italy

Pending

cell therapy

Biotechnology

Tender Offer

Single Bidder

gene therapy

Pharmaceuticals

Acquisition

Friendly

Majority

Public

Cross Border

Synopsis

Edit

AGC, a global contract development and manufacturing organization, offered to acquire Molmed, a biotechnology company, for $267m. AGC offered $0.577 per Molmed share, the equivalent of a premium of 110.3% compared to the stock’s closing price on March 16.

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US